Abstract Number: PB2091
Meeting: ISTH 2020 Congress
Theme: Venous Thromboembolism and Cardioembolism » Atrial Fibrillation
Background: During the last 40 years oral anticoagulant therapy has been managed in Italy in patients with atrial fibrillation (AF) and venous thromboembolism (VTE) by a network of Anticoagulation Centers (ACs). From 2013 onwards, direct oral anticoagulants (DOACs) have been made available. In patients taking DOACs, ACs have no longer performed periodical clinical and laboratory evaluations because of a different follow-up system, not requiring frequent blood withdrawal for the modification of the drug dosage. Since 2018 EGINA (Excellence model for the Integrated Management of New Anticoagulants) model has been used in 19 southern Italy ACs in order to improve the clinical management of patients taking DOACs.
Aims: The purpose of this study was to evaluate the incidence of ischemic and hemorrhagic events in patients taking DOACs, followed by ACs according to EGINA model.
Methods: 8 southern Italy ACs provided data on patients anticoagulated with DOACs. Patients with nonvalvular AF in anticoagulant prophylaxis with a DOAC, with a minimum observation time of 12 months, were included. Data were collected retrospectively.
Results: Overall 372 subjects with AF has been assessed. Mean age was 76.01 (ranging from 35 to 98 years old) and 179 patients were female (48.1%). On average CHA2D2-VASC score was 3.23 (SD= 1.23) and HAS-BLED 1.79 (SD= 0.95). Rivaroxaban was the most prescribed DOACs (36.8% of patients), followed by apixaban (25.8%), edoxaban (22.3%) and dabigatran (15.1%). The 36.6% of included subjects were naïve for anticoagulant therapy. Over 12-month follow-up, we observed an overall incidence of 2.7% for minor bleedings and of 1.3% for major bleedings. In our cohort, no ischemic event was observed.
Conclusions: EGINA model propose as a new protocol to be used by ACs for the clinical management of patients taking DOACs. Preliminary data from our registry show promising results with a low incidence of bleeding events.
To cite this abstract in AMA style:
Ciavarella N, Ciampa A, Bradamante S, Colucci A, Dirienzo G, Iannone AM, Polimeno G, Ria L, Scarafile R, Spagnolo M, Ciavarella A, Custodero C, Sabbà C. Preliminary Results from EGINA Registry: A New Model in the Management of Anticoagulation with DOACs in Southern Italy [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/preliminary-results-from-egina-registry-a-new-model-in-the-management-of-anticoagulation-with-doacs-in-southern-italy/. Accessed April 17, 2024.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/preliminary-results-from-egina-registry-a-new-model-in-the-management-of-anticoagulation-with-doacs-in-southern-italy/